Showing 1 - 10 of 28
Persistent link: https://www.econbiz.de/10013407315
Persistent link: https://www.econbiz.de/10014328027
Purpose – When practicing innovation, attracting different intellectual capabilities (ICAs) is extremely important. The reasoning is that innovation necessitates different ICA that can think differently together. Continuous pressure on finding, attracting and applying “the right intellectual...
Persistent link: https://www.econbiz.de/10014930729
Persistent link: https://www.econbiz.de/10005391177
Background: ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) showed in hypertensive patients that blood pressure-lowering treatment with an amlodipine-based regimen reduces events compared with an atenolol-based regimen and that atorvastatin was more effective than placebo. Abstract: Objective:...
Persistent link: https://www.econbiz.de/10005404770
Compared with olanzapine, the results suggest that quetiapine is cost effective as a maintenance treatment for bipolar depression. </AbstractSection> Copyright Springer International Publishing AG 2012
Persistent link: https://www.econbiz.de/10011001513
<Emphasis Type="Bold">Background: ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) showed in hypertensive patients that blood pressure-lowering treatment with an amlodipine-based regimen reduces events compared with an atenolol-based regimen and that atorvastatin was more effective than placebo. <Emphasis Type="Bold">Objective: To assess...</emphasis></emphasis>
Persistent link: https://www.econbiz.de/10011001519
The ATHENA clinical trial enrolled 4,628 patients in 37 countries and evaluated the efficacy of dronedarone 400 mg twice daily versus placebo for the prevention of cardiovascular hospitalisation or death from any cause in patients with paroxysmal or persistent atrial fibrillation or atrial...
Persistent link: https://www.econbiz.de/10010993826
Persistent link: https://www.econbiz.de/10010993993
Objective: To investigate the cost effectiveness of exemestane compared to megestrol in post-menopausal women after tamoxifen failure. Design and setting: A modelling study from the third-party payer perspective in Australia, Belgium, France, Germany, Italy, The Netherlands, Spain and the United...
Persistent link: https://www.econbiz.de/10004990329